Latest Content

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.

The ECHO study raises timely questions about whether managed care coverage policies have kept pace with evolving evidence.

The weekly anifrolumab autoinjector for systemic lupus erythematosus enables at-home use and improves convenience on top of standard therapy.

RSV vaccines and nirsevimab are linked to reduced infant hospitalizations, though seasonal spikes and data limitations remain concerns.

Radioligand therapy expands patient access in community oncology, pairing precision imaging with safe local delivery so patients stay close to home. This commentary will appear in the May issue of Evidence-Based Oncology.

MASH cirrhosis carries high risks of death, decompensation, and liver cancer—especially with type 2 diabetes—while predictive tools remain limited.

Psoriasis carries significant psychological and social burden, but adding mind-body approaches like CBT to treatment may improve mental health and outcomes.

The COA Community Oncology Conference will tackle AI, the rollout of bispecifics and CAR T in the community setting, plus reimbursement, radiation oncology, and patient access strategies.

Deuruxolitinib shows consistent efficacy across subgroups and drives early hair regrowth in severe alopecia areata, with gains seen by 8 weeks.